53 results about "Antithrombin Activity" patented technology

Glicosaminoglycans derived from K5 polysaccharide having high antithrombin activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified K5 polysaccharide by a process comprising the steps of N-deacetylation / N-sulphation, C5 epimerisation of at least 40% of the glucuronic acid moiety, O-oversulphation, selective O-desuphation, 6-O-sulphation, N-sulphation, and optional depolymeration, and in which the selective O-desulphation step is carried out by treatment of the oversulphated product with a mixture dimethyl sulfoxide / methanol at a temperature of 50-70C for 135-165 minutes. New, particularly interesting antithrombin compounds are obtained by thus controlling the reaction time in the selective O-desulphation step and submitting the product obtained at the end of the final N-sulphation step to depolymeration.

The invention relates to a preparation method of a clinical detection reagent and in particular relates to a preparation method of an antithrombase III activity determination kit. The preparation method of the antithrombase III activity determination kit comprises the following steps: dissolving lyophilized antithrombase powder and sodium heparin with Tris-HCl to form an S1 reagent, dissolving antithrombase chromogenic substrate S-2238 or Sar-Pro-Arg-P-nitroanilide with Tris-HCl to form an S2 reagent, lyophilizing the reagents S1 and S2 to form an S1 lyophilized product and an S2 lyophilized product; redissolving the S1 lyophilized product with Tris-HCl containing sodium azide solution to form an S1 lyophilized and redissolved reagent; dissolving the S2 lyophilized product with ultrapure water to form an S2 lyophilized and redissolved reagent; lyophilizing multi-person mixed plasma to prepare an ATIII calibrator; valuing the ATIII calibrator in the range of 90-110%; drawing a standard curve by adopting the valued ATIII calibrator, the S1 hyophilized and redissolved reagent and the S2 hyophilized and redissolved reagent, wherein linear correlation coefficient is larger than 0.99; and adding the S1 hyophilized and redissolved reagent and the S2 hyophilized and redissolved reagent into a to-be-detected plasma sample, and carrying out chromogenic reaction. The antithrombase III activity determination kit obtained by adopting the preparation method provided by the invention is low in cost, wide in linear range, good in stability and easy to use.

The invention provides a method capable of quickly increasing leech antithrombase active content. The method is simple and convenient in operation and can obtain high-quality leech medicinal materials. By adopting the method, overall antithrombase total content of leech is maximum in the 5th day after sucking, which is increased by 49.5%, 73.5%, 69.1% and 126.0% when compared with that in the 1stday, the 3rd day, the 7th day and the 11th day after sucking. By applying the method, antithrombase activity of the leech is improved remarkably without increasing production cost, and leech medicinalmaterial quality is improved.

The invention relates to a thrombin chromogenic substrate solution for determination of antithrombin III activity, a thrombin aqueous solution for determination of antithrombin III activity, a method for determination of antithrombin III activity in samples, a kit for determination of antithrombin III activity, application of sorbitol in preparation of the thrombin chromogenic substrate solution, and application of cane sugar in the chromogenic substrate method for determination of antithrombin III activity. The thrombin chromogenic substrate solution for determination of antithrombin III activity contains the thrombin chromogenic substrate, sorbitol and water. The thrombin chromogenic substrate solution can effectively be used for determination of antithrombin III activity.

Compositions and methods for preventing hematophagous infestation of cattle are provided, directed at isolated proteins with antithrombin activity and nucleotide sequences encoding the proteins. The proteins named thrombostasin is isolated from the salivary glands of Haematobia irritans. The compositions are useful as veterinary vaccines in prevention of blood-feeding in cattle by the infesting horn fly. The proteins of the invention are also useful in treatment of thrombosis.

The invention pertains to the field of medical technology and relates to a furo [2, 3-h] chromene compound and an application thereof for inhibiting platelet aggregation; the furo [2, 3-h] chromene compound, pharmaceutically-acceptable salt, or stereo-isomers and pre-drugs of the furo [2, 3-h] chromene compound, as well as pharmaceutical compatibility acceptable carriers or diluents of the furo [2, 3-h] chromene compound can be used as platelet aggregation inhibitors. The structural formula of the furo [2, 3-h] chromene compound is as shown above, wherein, X can be chosen from CH2 or C=O, R1 can be independently chosen from H or a substituted or un-substituted aromatic base, R2 can be independently chosen from H or a substituted or un-substituted aromatic base, and R can be independently chosen from H, alkyl group with one to four carbon atoms, chlorine, bromine, fluorin, methoxyl, nitryl or hydroxyl. The furo [2, 3-h] chromene compound has simple synthetic method, adapts to industrialized production and is more stable compared with natural analogues. Shown by biological activity assay, the furo [2, 3-h] chromene compound has antithrombin activity and is a platelet aggregation inhibiting drug.